Background: Percutaneous coronary intervention (PCI), the most common method in treating coronary artery disease (CAD), has a variety of side effects. Yiqi Huoxue therapy (YQHX) can effectively alleviate the symptoms of patients and reduce the side effects. However, a reliable and systematic assessment of the methodologies is not available.
Methods: Seven electronic databases were searched to identify randomized controlled trials of YQHX method for CAD after PCI. The quality assessment of the trials included was performed by employing the Cochrane Risk of Bias tool.
Results: One thousand eight hundred sixty-eight patients from 23 randomized controlled trials were included in this review. The aggregated results showed that the experimental group got better effect in increasing ORR, TCMSRR, ECG, HDL-C, and in lowering the level of CRP, TC, and MACE in comparison with the control group.
Conclusion: YQHX method is a valid complementary and alternative therapy in the management of CAD after PCI, and is an effective and safe therapy for CAD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575818 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000030739 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corrigendum to "Bushen Huoxue Yiqi formula alleviates cardiac fibrosis in ischemic heart failure through SIRT1/Notch1 pathway-mediated EndMT" [Phytomedicine Journal 135 (2024) 156252].
Phytomedicine
December 2024
Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, Beijing 100053, China.
Bushen Huoxue Yiqi formula alleviates cardiac fibrosis in ischemic heart failure through SIRT1/Notch1 pathway-mediated EndMT.
Phytomedicine
December 2024
Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, No.5, beixiange, Xicheng District, Beijing 100053, China.
Background: Cardiac fibrosis plays a crucial role in the development of heart failure (HF) following myocardial infarction (MI). Endothelial-mesenchymal transition (EndMT) is one of the key drivers of cardiac fibrosis and subsequent cardiac dysfunction. The traditional Chinese medicine formula Bushen Huoxue Yiqi Formula (BHYF) is an effective prescription for treating HF, significantly improving cardiac function in patients.
View Article and Find Full Text PDFEfficacy of different traditional Chinese medicine decoctions in the treatment of ischemic stroke: a network meta-analysis.
Front Pharmacol
November 2024
College of Integrated Chinese and Western Medicine, Changchun University of Chinese Medicine, Changchun, China.
Objective: Currently, traditional Chinese medicine (TCM) and its combinations are widely used in the treatment and rehabilitation of patients with ischemic stroke. However, current studies should mainly focus on the therapeutic effects of traditional Chinese medicines alone. This paper will employ a network meta-analysis to compare the efficacy of different TCM decoctions in the treatment of patients with ischemic stroke.
View Article and Find Full Text PDFBased on SIRT1/NF-κB/NLRP3 Signal Pathway to Explore the Effect of Yiqi Huatan Huoxue Recipe on Inflammatory Injury in AIT Mice by Pyroptosis.
Comb Chem High Throughput Screen
August 2024
The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110034, China.
Objective: Autoimmune thyroiditis (AIT) is the most common autoimmune thyroid disease. In recent decades, its incidence and prevalence have sharply increased. Yiqi Huatan Huoxue recipe is a traditional Chinese medicine formula we use to treat AIT.
View Article and Find Full Text PDF[Network Meta-analysis of Chinese patent medicines in treatment of chronic pulmonary heart disease].
Zhongguo Zhong Yao Za Zhi
July 2024
Department of Cardiovascular Diseases, the First Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou 450000, China.
Article Synopsis
- A network meta-analysis was conducted to evaluate the effectiveness and safety of various Chinese patent medicines for treating chronic pulmonary heart disease, analyzing data from numerous databases including CNKI, PubMed, and Cochrane Library, up to December 2023.
- The analysis included 95 randomized controlled trials (RCTs) with a total of 8,787 patients and assessed multiple Chinese patent medicines, focusing on metrics like cardiac function, forced expiratory volume, and partial pressure of gases in the blood.
- Top-performing treatments combined Chinese medicines with conventional western medicines, including Wenxin Granules, Tongxinluo Capsules, and Qishen Yiqi Dropping Pills for overall efficacy and improvements in respiratory function.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!